Evidence map›Paper›PMID 35282450›Full record

ArticleFrontiers in endocrinology2022

Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis.

Yadong Guo, Anil Shrestha, Niraj Maskey, Xiaohui Dong, Zongtai Zheng, Fuhan Yang, Ruiliang Wang, Wenchao Ma, Ji Liu, Cheng Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yadong GuoDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Anil ShresthaDepartment of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal.
Niraj MaskeyDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Xiaohui DongDepartment of General Medical, Shanghai Fourth People's Hospital, Tongji University, Shanghai, China.
Zongtai ZhengDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Fuhan YangDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Ruiliang WangDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Wenchao MaDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Ji LiuDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Cheng LiDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Wentao ZhangDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Shiyu MaoDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Aihong ZhangDepartment of Medical Statistics, Tongji University School of Medicine, Shanghai, China.
Shenghua LiuDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Xudong YaoDepartment of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clear cell adenocarcinoma (CCA) is considered a relatively rare tumor with a glycogen-rich phenotype. The prognosis of CCA patients is unclear. In this study, recent trends in the epidemiological and prognostic factors of CCA were comprehensively investigated. Methods: Patients with CCA from years 2000 to 2016 were identified from the Surveillance, Epidemiological, and End Results (SEER) database. Relevant population data were used to analyze the rates age-adjusted incidence, age-standardized 3-year and 5-year relative survivals, and overall survival (OS). Results: The age-adjusted incidence of CCA increased 2.7-fold from the year 2000 (3.3/100,000) to 2016 (8.8/100,000). This increase occurred across all ages, races, stages, and grades. Of all these subgroups, the increase was largest in the grade IV group. The age-standardized 3-year and 5-year relative survivals increased during this study period, rising by 9.1% and 9.5% from 2000 to 2011, respectively. Among all the stages and grades, the relative survival increase was greatest in the grade IV group. According to multivariate analysis of all CCA patients, predictors of OS were: age, gender, year of diagnosis, marital status, race, grade, stage, and primary tumor site ( Conclusions: The incidence of CCA and survival of these patients improved over time. In particular, the highest increases were reported for grade IV CCA, which may be due to an earlier diagnosis and improved treatment.

Indexed as

Adenocarcinoma, Clear CellDatabases, FactualHumansIncidencePrognosisSEER Programclear cell adenocarcinomaglycogen-rich phenotypeincidenceSEER databasesurvival

Identifiers

PMID35282450
PMCPMC8907425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.